| 翻訳と辞書 |
| Diamyd Medical ： ウィキペディア英語版 |
Diamyd Medical
Diamyd Medical AB () is a Swedish medical research company, listed on the Stockholm Stock Exchange. Diamyd's research utilises two different platform technologies. One is based on the GAD65 molecule, which is used in a vaccine that has proven effective in delaying the destruction of beta cells associated with type 1 diabetes, the other on a system to deliver substances directly to nerve cells. The use of GAD65 for therapeutic purposes is licensed from the University of California, Los Angeles. In March, 2008 Diamyd's application for a phase III trial in the United States was approved by the U.S. Food and Drug Administration. The company will perform a parallel phase III trial in Europe.
==Product portfolio==
Diamyd, a (GAD65 based, type 1 diabetes vaccine). Injections with GAD65, an autoantigen involved in type 1 diabetes, has in clinical trials delayed the destruction of beta cells for at least 30 months, without serious adverse effects.〔(Presentation from the Extra General Shareholders Meeting on March 10, 2008: In the treatment of Diabetes and Diabetes related complications )〕 Patients treated with the substance showed higher levels of regulatory cytokines, thought to protect the beta cells.〔(New England Journal of Medicine: GAD Treatment and Insulin Secretion in Recent-Onset Type 1 Diabetes )〕 Phase III trials are under way in the USA and in Europe.〔(Further Evidence for Lasting Immunological Efficacy of Diamyd Diabetes Vaccine )〕〔(Diamyd Announces Completion of Type 1 Diabetes Vaccine Trial with Long Term Efficcacy Demonstrated at 30 Months )〕 Future applications can include latent autoimmune diabetes〔(Beta cell function and metabolic control during two years of follow-up after GAD65 dose-escalation immunomodulation in adult-onset autoimmune diabetes )〕 and prevention of type 1 diabetes.〔(New England Journal of Medicine:Immunotherapy on Trial for New-Onset Type 1 Diabetes )〕 Two prevention studies will start in 2009.〔(MSNBC News: Pioneering Diamyd(r) Study to Prevent Childhood Diabetes Approved )〕〔(Diamyd press release: Diamyd approved for groundbreking study in Norway )〕
NTDDS (Nerve Targeting Drug Delivery System) - A viral delivery system of proteins to nervous tissue (Nerve Targeted Drug Delivery System, NTDDS) that can be used e.g. against chronic pain. A phase I trial has shown positive results.〔(Annals of Neurology: Gene therapy for pain: ''Results of a phase I clinical trial'', )〕
抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』
■ウィキペディアで「Diamyd Medical」の詳細全文を読む
スポンサード リンク
| 翻訳と辞書 : 翻訳のためのインターネットリソース |
Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.
|
|